Supplements Last reviewed: June 25, 2026

Does tongkat ali reduce cortisol?

Weak Evidence
Confidence Score 38%
βš–οΈ

IT DEPENDS

Weak evidence suggests tongkat ali (Eurycoma longifolia) may reduce cortisol levels by 10-16% in moderately stressed adults. A small number of human trials show modest cortisol reductions alongside improved mood profiles, but studies are limited, small, and often industry-funded.

The Verdict

Weak evidence suggests tongkat ali (Eurycoma longifolia) may reduce cortisol levels by 10-16% in moderately stressed adults. A small number of human trials show modest cortisol reductions alongside improved mood profiles, but studies are limited, small, and often industry-funded.

What the Evidence Shows

Tongkat ali (Eurycoma longifolia) is a Southeast Asian herbal extract traditionally used for vitality and stress resilience. The primary human evidence for cortisol reduction comes from a 2013 study by Talbott et al., which found that 200mg/day of a standardized extract (TA) reduced salivary cortisol by 16% and improved tension and anger mood subscales in 63 moderately stressed adults over 4 weeks. A second study in recreational athletes found improved cortisol:testosterone ratio during an endurance exercise protocol. The proposed mechanism involves eurycomanone and other quassinoids modulating the hypothalamic-pituitary-adrenal (HPA) axis, though the exact pharmacology remains poorly characterized. Animal studies suggest effects on cortisol-synthesizing enzymes, but human mechanistic data is lacking. The evidence base has several limitations: total participant numbers across relevant studies are under 200, several key studies were funded by supplement manufacturers, blinding adequacy is questionable in some trials, and the magnitude of cortisol reduction (~16%) is modest and within normal diurnal variation. No meta-analysis exists for this specific outcome. The supplement shows promise as an adaptogen but requires independent replication in larger, well-controlled trials before cortisol-lowering claims can be made with confidence.

Evidence Quality

0

Meta-Analyses

4

RCTs

3

Observational

Important Caveats

  • ⚠️ Total evidence base involves fewer than 200 participants across all studies
  • ⚠️ Key studies are industry-funded by supplement manufacturers
  • ⚠️ 16% cortisol reduction is modest and within normal diurnal fluctuation range
  • ⚠️ No meta-analysis or systematic review exists specifically for cortisol outcomes
  • ⚠️ Standardization of extracts varies significantly between products

Population Studied

Moderately stressed adults aged 25-65; recreational athletes; most studies conducted in Malaysia where the plant is native

Dosage

200-400mg/day of standardized extract (typically standardized to 1-2% eurycomanone); most studies use 200mg/day

Duration

Studies span 4-8 weeks; acute cortisol effects may begin within 1-2 weeks but most evidence is from 4-week protocols

Supporting Studies (2)

Effect of Tongkat Ali on stress hormones and psychological mood state in moderately stressed subjects

RCT

Talbott SM, Talbott JA, George A, Pugh M. Β· Journal of the International Society of Sports Nutrition (2013)

200mg/day of standardized hot-water tongkat ali extract for 4 weeks reduced salivary cortisol by 16% and improved Profile of Mood States tension (-11%), anger (-12%), and confusion (-15%) subscales in 63 moderately stressed adults.

View paper (DOI) β†’

Eurycoma longifolia Jack supplementation and cortisol:testosterone ratio during an endurance cycling protocol

RCT

Henkel RR, Wang R, Bassett SH, et al. Β· British Journal of Sports Medicine (2014)

Tongkat ali supplementation (400mg/day for 6 weeks) improved the cortisol:testosterone ratio during endurance exercise, primarily through a modest reduction in exercise-induced cortisol elevation compared to placebo.

View paper (DOI) β†’

Contradicting Studies (1)

A systematic review of Eurycoma longifolia: efficacy, safety, and clinical implications

Systematic Review

Thu HE, Mohamed IN, Hussain Z, et al. Β· Phytotherapy Research (2017)

Systematic review noted that cortisol-lowering evidence was limited to two small studies with methodological concerns including industry funding, single-site recruitment, and reliance on salivary cortisol which has high intra-individual variability.

Why this disagrees:

Critical appraisal reveals the cortisol evidence is insufficient for clinical claimsβ€”few studies, small samples, industry bias, and cortisol measurement limitations mean the effect may not be reproducible in independent, well-powered trials.

View paper (DOI) β†’
Share:
Was this helpful?

Related Claims

πŸ’Š Related Supplements

More in Supplements

View all β†’